IDIA.SW Idorsia closes CHF 3.65 on 30 Jan 2026 (SIX): Active trade clues
IDIA.SW stock closed at CHF 3.65 on 30 Jan 2026 on the SIX after trading 1,151,119.00 shares, making Idorsia one of the most active healthcare names in Switzerland today. We saw a small intraday range from CHF 3.64 to CHF 3.81, with the 50-day average at CHF 3.80 and the 200-day average at CHF 2.99. The move comes ahead of Idorsia’s next earnings date on 26 Feb 2026, and traders are watching pipeline updates and partner revenues. This market-closed note focuses on price action, valuation, technicals, catalysts, and our model outlook for IDIA.SW stock.
Price action and volume: IDIA.SW stock session details
Idorsia (IDIA.SW) ended the session at CHF 3.65 after opening at CHF 3.75. Volume reached 1,151,119.00, below the 30-day average of 1,454,935.00, but still enough to rank it among today’s most active Swiss small-caps. The one-day change was +0.03 or +0.97%, while the one-year change is +410.83%.
Fundamentals and valuation: IDIA.SW stock metrics
Idorsia reports EPS -0.62 and PE -5.90, reflecting ongoing negative earnings and development spending. Market cap is CHF 729,465,865.00 with 199,580,264.00 shares outstanding. Price-to-sales sits near 3.10, and cash per share is 0.33, showing a tight cash runway relative to enterprise value.
Technical picture: IDIA.SW stock indicators
Momentum is mixed: RSI is 45.41 and MACD histogram is -0.03. The 50-day moving average (CHF 3.80) sits above price, and the 200-day moving average (CHF 2.99) supports longer-term strength. Volatility shows ATR 0.29, and Bollinger bands run 3.45 to 4.55, suggesting room for range trading.
Catalysts and news flow: IDIA.SW stock drivers
Key catalysts include the 26 Feb 2026 earnings announcement and trial updates for CNS and cardiovascular assets. Idorsia’s partnerships with Janssen and Mochida remain potential revenue drivers. We link company details and wider coverage for context: Idorsia company site and market news source Bloomberg profile for Swiss stocks.
Meyka grade and forecast: IDIA.SW stock rating
Meyka AI rates IDIA.SW with a score of 68.88 out of 100 — Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of CHF 5.91, implying +62.00% vs the current CHF 3.65. Forecasts are model-based projections and not guarantees.
Risks and positioning: IDIA.SW stock outlook
Downside risks include continued negative EPS, cash burn, and trial setbacks. Balance-sheet ratios show enterprise value to sales near 8.27, and interest coverage is negative. We recommend position sizing that reflects high biotech volatility and event-driven catalysts ahead of earnings.
Final Thoughts
Key takeaways for IDIA.SW stock: Idorsia closed at CHF 3.65 on the SIX with 1,151,119.00 shares traded, keeping it among Switzerland’s most active small-caps today. Fundamentals show negative EPS -0.62 and a negative PE, while technicals point to a neutral momentum band. Meyka AI’s forecast model projects a yearly price of CHF 5.91, implying +62.00% upside versus the current price. Near-term catalysts include the 26 Feb 2026 earnings release and clinical-readout announcements from partner programs. We view the stock as event-driven and recommend careful sizing for traders. Remember, Meyka AI is an AI-powered market analysis platform; our grade and forecasts are model outputs and not investment guarantees. Monitor cash metrics, partner revenues, and trial data for directional conviction.
FAQs
What moved IDIA.SW stock today?
IDIA.SW stock moved on volume of 1,151,119.00 shares and a close at CHF 3.65. Traders flagged upcoming earnings on 26 Feb 2026 and clinical program updates as the main drivers.
What is Meyka AI’s view on IDIA.SW stock?
Meyka AI rates IDIA.SW at 68.88/100 (Grade B, HOLD). The model highlights event-driven upside but flags negative EPS and cash burn as risks to watch.
What price targets and forecasts exist for IDIA.SW stock?
Internal forecasts show a monthly CHF 3.73 and a yearly CHF 5.91, implying near-term upside. Forecasts are projections from Meyka AI models and not guarantees.
How should investors manage risk in IDIA.SW stock?
Manage risk with small, event-driven positions and stop guidelines. IDIA.SW stock has negative earnings and clinical risk, so diversify and track partner revenue updates closely.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
